Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates
Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates Cambridge, Mass. – September 20, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and
View HTML
Toggle Summary Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference
Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference Cambridge, Mass. – September 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf,
View HTML
Toggle Summary Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer
Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer Cambridge, MA – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John L.
View HTML
Toggle Summary Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
Encouraging safety and biological activity supports advancement into phase 2 studies
View HTML
Toggle Summary Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting
Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting CAMBRIDGE, MA – August 6, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it will present the
View HTML
Toggle Summary Pharmaceutical Executive: Acceleron Pharma’s Pipeline Selected to Top 7 Most Exciting Future Therapies and Technologies
Pharmaceutical Executive: Acceleron Pharma’s Pipeline Selected to Top 7 Most Exciting Future Therapies and Technologies Pharmaceutical Executive, August 1, 2007
View HTML
Toggle Summary Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference
Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference CAMBRIDGE, MA – July 31, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that company President and Founder, John Knopf, Ph.D., will provide a
View HTML
Toggle Summary Boston Globe: Super-buff cattle may hold key to treating muscular diseases
Boston Globe: Super-buff cattle may hold key to treating muscular diseases Link to article
View HTML
Toggle Summary ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
Novel Approach Represents a Significant Advance for the Treatment of Cancer-related Bone Loss
View HTML
Toggle Summary Start-Up: Acceleron Pharma, Inc.-Releasing the Brakes on Bone and Muscle Growth
Start-Up: Acceleron Pharma, Inc.-Releasing the Brakes on Bone and Muscle Growth Start-Up: June 1, 2007
View HTML